Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medical device
|
| gptkbp:administeredBy |
injection
|
| gptkbp:alternativeTo |
rectal balloons
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:Europe
gptkb:United_States |
| gptkbp:category |
radiation oncology device
urology device |
| gptkbp:clinicalTrialPhase |
NCT01538628
|
| gptkbp:composition |
polyethylene glycol hydrogel
|
| gptkbp:degradedBy |
water and carbon dioxide
|
| gptkbp:durationInBody |
about 6 months
|
| gptkbp:function |
protects rectum during prostate radiation
|
| https://www.w3.org/2000/01/rdf-schema#label |
SpaceOAR Hydrogel
|
| gptkbp:location |
between prostate and rectum
|
| gptkbp:manufacturer |
gptkb:Boston_Scientific
|
| gptkbp:marketedAs |
Augmenix (acquired by Boston Scientific)
|
| gptkbp:reduces |
rectal radiation dose
rectal toxicity |
| gptkbp:regulates |
CE marked
FDA approved |
| gptkbp:sideEffect |
bleeding
infection pain at injection site urinary symptoms |
| gptkbp:usedFor |
prostate cancer radiation therapy
|
| gptkbp:bfsParent |
gptkb:Augmenix
|
| gptkbp:bfsLayer |
6
|